Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells

Elias Zambidis, Tea Soon Park, Wei Yu, Ada Tam, Michal Levine, Xuan Yuan, Marina Pryzhkova, Bruno Péault

Research output: Contribution to journalArticle

Abstract

We report that angiotensin-converting enzyme (ACE), a critical physiologic regulator of blood pressure, angiogenesis, and Inflammation, Is a novel marker for identifying hemangioblasts differentiating from human embryonic stem cells (hESC). We demonstrate that ACE+CD45-CD34 +/- hemangloblasts are common yolk sac (YS)-like progenitors for not only endothelium but also both primitive and definitive human lymphohematopoietic cells. Thrombopoletin and basic fibroblast growth factor are identified as critical factors for the proliferation of human hemangioblasts. The developmental sequence of human embryoid body hematopoiesis is remarkably congruent to the timeline of normal human YS development, which occurs during weeks 2 to 6 of human gestation. Furthermore, ACE and the reninangiotensin system (RAS) directly regulate hemangioblast expansion and differentiation via signaling through the angiotensin II receptors AQTR1 and AGTR2. ACE enzymatic activity is required for hemangioblast expansion, and differentiation toward either endothelium or multipotent hematopoietic progenitors is dramatically augmented after manipulation of angiotensin Il signaling with either AGTR1- or AGTR2-specific Inhibitors. The RAS can therefore be exploited to direct the hematopoietic or endothelial fate of hESC-derlved hemangioblasts, thus providing novel opportunities for human tissue engineering. Moreover, the initial events of human hematoendothellogenesis can be delineated In a manner previously Impossible because of inaccessibility to early human embryonic tissues.

Original languageEnglish (US)
Pages (from-to)3601-3614
Number of pages14
JournalBlood
Volume112
Issue number9
DOIs
StatePublished - Nov 1 2008

Fingerprint

Hemangioblasts
Pluripotent Stem Cells
Peptidyl-Dipeptidase A
Stem cells
Yolk Sac
Angiotensin Receptors
Endothelium
Blood pressure
Angiotensins
Fibroblast Growth Factor 2
Tissue engineering
Embryoid Bodies
Human Engineering
Hematopoiesis
Tissue Engineering
Tissue
Human Body
Blood Pressure
Inflammation
Pregnancy

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. / Zambidis, Elias; Park, Tea Soon; Yu, Wei; Tam, Ada; Levine, Michal; Yuan, Xuan; Pryzhkova, Marina; Péault, Bruno.

In: Blood, Vol. 112, No. 9, 01.11.2008, p. 3601-3614.

Research output: Contribution to journalArticle

@article{442c2ad7cf6e4dbc9637bf75efe64758,
title = "Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells",
abstract = "We report that angiotensin-converting enzyme (ACE), a critical physiologic regulator of blood pressure, angiogenesis, and Inflammation, Is a novel marker for identifying hemangioblasts differentiating from human embryonic stem cells (hESC). We demonstrate that ACE+CD45-CD34 +/- hemangloblasts are common yolk sac (YS)-like progenitors for not only endothelium but also both primitive and definitive human lymphohematopoietic cells. Thrombopoletin and basic fibroblast growth factor are identified as critical factors for the proliferation of human hemangioblasts. The developmental sequence of human embryoid body hematopoiesis is remarkably congruent to the timeline of normal human YS development, which occurs during weeks 2 to 6 of human gestation. Furthermore, ACE and the reninangiotensin system (RAS) directly regulate hemangioblast expansion and differentiation via signaling through the angiotensin II receptors AQTR1 and AGTR2. ACE enzymatic activity is required for hemangioblast expansion, and differentiation toward either endothelium or multipotent hematopoietic progenitors is dramatically augmented after manipulation of angiotensin Il signaling with either AGTR1- or AGTR2-specific Inhibitors. The RAS can therefore be exploited to direct the hematopoietic or endothelial fate of hESC-derlved hemangioblasts, thus providing novel opportunities for human tissue engineering. Moreover, the initial events of human hematoendothellogenesis can be delineated In a manner previously Impossible because of inaccessibility to early human embryonic tissues.",
author = "Elias Zambidis and Park, {Tea Soon} and Wei Yu and Ada Tam and Michal Levine and Xuan Yuan and Marina Pryzhkova and Bruno P{\'e}ault",
year = "2008",
month = "11",
day = "1",
doi = "10.1182/blood-2008-03-144766",
language = "English (US)",
volume = "112",
pages = "3601--3614",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells

AU - Zambidis, Elias

AU - Park, Tea Soon

AU - Yu, Wei

AU - Tam, Ada

AU - Levine, Michal

AU - Yuan, Xuan

AU - Pryzhkova, Marina

AU - Péault, Bruno

PY - 2008/11/1

Y1 - 2008/11/1

N2 - We report that angiotensin-converting enzyme (ACE), a critical physiologic regulator of blood pressure, angiogenesis, and Inflammation, Is a novel marker for identifying hemangioblasts differentiating from human embryonic stem cells (hESC). We demonstrate that ACE+CD45-CD34 +/- hemangloblasts are common yolk sac (YS)-like progenitors for not only endothelium but also both primitive and definitive human lymphohematopoietic cells. Thrombopoletin and basic fibroblast growth factor are identified as critical factors for the proliferation of human hemangioblasts. The developmental sequence of human embryoid body hematopoiesis is remarkably congruent to the timeline of normal human YS development, which occurs during weeks 2 to 6 of human gestation. Furthermore, ACE and the reninangiotensin system (RAS) directly regulate hemangioblast expansion and differentiation via signaling through the angiotensin II receptors AQTR1 and AGTR2. ACE enzymatic activity is required for hemangioblast expansion, and differentiation toward either endothelium or multipotent hematopoietic progenitors is dramatically augmented after manipulation of angiotensin Il signaling with either AGTR1- or AGTR2-specific Inhibitors. The RAS can therefore be exploited to direct the hematopoietic or endothelial fate of hESC-derlved hemangioblasts, thus providing novel opportunities for human tissue engineering. Moreover, the initial events of human hematoendothellogenesis can be delineated In a manner previously Impossible because of inaccessibility to early human embryonic tissues.

AB - We report that angiotensin-converting enzyme (ACE), a critical physiologic regulator of blood pressure, angiogenesis, and Inflammation, Is a novel marker for identifying hemangioblasts differentiating from human embryonic stem cells (hESC). We demonstrate that ACE+CD45-CD34 +/- hemangloblasts are common yolk sac (YS)-like progenitors for not only endothelium but also both primitive and definitive human lymphohematopoietic cells. Thrombopoletin and basic fibroblast growth factor are identified as critical factors for the proliferation of human hemangioblasts. The developmental sequence of human embryoid body hematopoiesis is remarkably congruent to the timeline of normal human YS development, which occurs during weeks 2 to 6 of human gestation. Furthermore, ACE and the reninangiotensin system (RAS) directly regulate hemangioblast expansion and differentiation via signaling through the angiotensin II receptors AQTR1 and AGTR2. ACE enzymatic activity is required for hemangioblast expansion, and differentiation toward either endothelium or multipotent hematopoietic progenitors is dramatically augmented after manipulation of angiotensin Il signaling with either AGTR1- or AGTR2-specific Inhibitors. The RAS can therefore be exploited to direct the hematopoietic or endothelial fate of hESC-derlved hemangioblasts, thus providing novel opportunities for human tissue engineering. Moreover, the initial events of human hematoendothellogenesis can be delineated In a manner previously Impossible because of inaccessibility to early human embryonic tissues.

UR - http://www.scopus.com/inward/record.url?scp=55749104551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55749104551&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-03-144766

DO - 10.1182/blood-2008-03-144766

M3 - Article

C2 - 18728246

AN - SCOPUS:55749104551

VL - 112

SP - 3601

EP - 3614

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -